<DOC>
	<DOCNO>NCT00317564</DOCNO>
	<brief_summary>This prospective , observational , registration follow-up study woman expose Betaseron® time conception ( i.e. , time first day last menstrual period ) and/or pregnancy . The Betaseron® Pregnancy Registry design determine whether increase risk pattern birth defect offspring woman expose Betaseron® conception pregnancy compare rate woman general US population . Secondarily , Registry examine rate spontaneous abortion negative pregnancy outcome population . This study conduct United States ( US ) . The Betaseron® Pregnancy Registry sponsor Bayer HealthCare Pharmaceuticals manage Post Approval &amp; Strategic Services group INC Research , LLC . The scientific conduct analysis Registry overseen Independent Data Safety Monitoring Board ( IDSMB ) consist external specialist teratology , epidemiology , maternal fetal medicine , neurology ( external member detail available upon request ) .</brief_summary>
	<brief_title>Betaseron Pregnancy Registry</brief_title>
	<detailed_description>Because informed consent require , Registration process must initiate patient . An HCP contact Registry may request authorization release medical information packet eligible patient contact Registry directly . Once eligible subject provide consent permission obtain information HCP , Registry contact obstetric HCP obtain information demographic , history previous pregnancy , maternal risk factor , pregnancy outcome , neonatal health . Data collect maternal HCP enrollment , second trimester ( around week 20 ) , outcome . Data live born infant collect pediatrician 4 month age . If birth defect report , target follow-up may conduct . NOTE : This study previously post Berlex , Inc. since rename Bayer HealthCare Pharmaceuticals , Inc. Bayer HealthCare Pharmaceuticals , Inc. sponsor pregnancy registry .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Pregnancy Complications</mesh_term>
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>The subject must meet follow criterion registration : Enroll prospectively ( patient still pregnant structural defect note prenatal test ) Diagnosed MS prior current pregnancy Exposed Betaseron® first day patient 's last menstrual period Provide verbal consent participate Registry Verbally provide contact information , HCP , infant 's HCP ( applicable )</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Birth Defects</keyword>
	<keyword>High Risk Pregnancy</keyword>
	<keyword>Multiple Sclerosis</keyword>
</DOC>